Introduction {#s1}
============

Alcohol is the most ubiquitously consumed mind-altering substance in the world, and it is considered responsible for 25% of the mortality in people aged 20--30. The lifetime prevalence of alcohol use disorder (AUD) in the United States is estimated to be 29.1% ([@B19]; [@B18]).

AUD is a multifactorial complex disorder with multiple genes and environmental factors interacting to produce the phenotype of addiction ([@B30]). [**Table 1**](#T1){ref-type="table"} illustrates the 11 diagnostic criteria of AUD according to the most recent edition of the *Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition* (DSM-V) ([@B3]). Notably, while tolerance and withdrawal were already among the criteria in previous editions, this edition includes craving for the first time, likely to convey the importance of behavioral over pharmacological components.

###### 

Alcohol use disorder (AUD) diagnostic criteria.

  Category                     Criteria                                                                                      Description
  ---------------------------- --------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------
  Impaired control             C1                                                                                            Drinking more than intended
  C2                           Unable to cut down or stop drinking                                                           
  C3                           Spending a lot of time drinking or recovering from drinking                                   
  C4                           Wanting a drink so badly you can't think of anything else (craving)                           
  Social impairment            C5                                                                                            Drinking interferes with home, family, job, or school
  C6                           Drinking even though it causes trouble with friends or family                                 
  C7                           Giving up on important activities to drink instead                                            
  Risky use                    C8                                                                                            Drinking and getting into situations that increase chances of getting hurt
  C9                           Continuing to drink despite becoming anxious, depressed, or experiencing memory blackout      
  Pharmacological indicators   C10                                                                                           Needing to drink more to feel the same effect (tolerance)
  C11                          Experiencing withdrawal symptoms such as restlessness, nausea, seizures, and hallucinations   

The 11 criteria used to characterize AUD can be divided into four categories---impaired control, social impairment, risky use, and pharmacological indicators. Severity of AUD is defined by the number of symptoms present (2--3: mild, 4--5: moderate, 6 or more: severe) ([@B3]).

The negative impact of alcohol on health makes the discovery of novel potential therapeutic targets for AUD the subject of extensive research. One of these has been identified in Sigma receptors (Sig-Rs). Two subtypes of Sig-Rs have been identified, sigma-1 receptor (Sig-1R) and sigma-2 receptor (Sig-2R); this review will focus exclusively on the available evidence concerning Sig-1R. Indeed, since Sig-2R was only cloned in 2017 ([@B1]), very few selective ligands have been available and, therefore, most evidence in the context of alcohol and other addictions has been obtained using either non-selective Sig-1R/Sig-2R or Sig-1R selective ligands. Specifically, we will summarize research showing that manipulations of Sig-1R impact ethanol-induced changes in locomotor function, acquisition and expression of conditioned place preference (CPP), alcohol consumption and seeking behavior, and reinstatement of alcohol-seeking behavior, as well as deficits in cognitive function induced by alcohol.

Sigma Receptors {#s1_1}
---------------

Two subtypes of Sig-Rs have been described: Sig-1R and Sig-2R. While both are sensitive to haloperidol and 1,3-di(2-tolyl)guanidine, Sig-1Rs are more sensitive to benzomorphans such as (+)-SKF-10,047, dextromethorphan, and carbetapentane ([@B11]). In addition, the two receptor subtypes differ in size, with Sig-1R having a larger molecular weight ([@B1]). Proposed endogenous ligands include N,N-dimethyltryptamine and neurosteroids ([@B16]); interestingly, psychostimulants, such as cocaine, lidocaine, and methamphetamine, have all been shown to bind Sig-1R, although with rather weak affinity ([@B63]; [@B46]).

### Sig-1R Structure and Localization {#s1_1_1}

Sig-1R is a 25--29 kDa protein encoded by the *SIGMAR1* gene ([@B50]). In 2016, Schmidt and colleagues solved the crystal structure of human Sig-1R and found it to be a trimer, with each protomer containing one transmembrane domain ([@B62]). The gene that encodes the human Sig-1R is found on band p13 of chromosome 9 and is ∼7 kbp long, coding four exons (encoding a 25.3 kDa protein) and three introns ([@B6]; [@B36]). Although Sig-1R shows no homology with any other known mammalian proteins, Sig-1R shares 30% identity and 67% similarity with a yeast sterol isomerase, consistent with the observation that sterol-producing tissues have high levels of Sig-1R mRNA ([@B7]).

Sig-1Rs are found both intracellularly and on the plasma membrane ([@B6]). Specifically, they have been shown to be extensively associated with cholesterol-enriched loci on the endoplasmic reticulum, as well as on the mitochondrion-associated endoplasmic reticulum membrane ([@B2]; [@B20]; [@B21]). Upon activation, the receptors move laterally toward the periphery of the cell ([@B21]). Sig-1Rs have been shown to be in cell bodies and on dendrites, but not on axon terminals or fibers table ([@B2]).

### Receptor signaling {#s1_1_2}

Sig-1R has been shown to associate with a variety of proteins such as ankyrin B, heat shock protein 70, phospholipase C, and thus protein kinase C (PKC), protein kinase A, and glucose-related protein/immunoglobulin heavy-chain-binding protein, among others ([@B42]; [@B20]; [@B36]; [@B22]; [@B28]). In addition, Sig-1Rs modulate voltage-gated ion channels, such as the N-type Ca^2+^ channel, Nav1.5, Kv1.2, Kv1.3, Kv1.4, and Kv1.5 ([@B6]; [@B7]; [@B29]; [@B31]; [@B32]; [@B68]). While Sig-1Rs are not G-protein coupled, they physically associate with certain G-protein coupled receptors, such as mu opioid and dopamine D1 and D2 receptors, modulating their activity ([@B27]; [@B44]; [@B45]). Additional studies determined that Sig-1R also modulates dopamine transporters ([@B25]).

Sig-1R activation has been shown to potentiate *N*-methyl-*D*-aspartate receptor (NMDAR)-induced Ca^2+^ influx, mainly through the facilitation of PKC-mediated phosphorylation of the GluN1 subunit ([@B53]). Sig-1R activation has also been linked to increased GluN2a, GluN2b, and postsynaptic density protein 95 expression, as well as to NMDAR subunit redistribution and increased NMDAR trafficking to the synapse ([@B48]). In addition, Sig-1R activation potentiates the release of several neurotransmitters, such as acetylcholine, dopamine, and brain-derived neurotrophic factor ([@B4]; [@B37]; [@B17]), all of which are perturbed in AUD ([@B43]; [@B13]; [@B67]). This indicates Sig-1R as a critically important target for the study of AUD.

Sigma Receptors and Locomotor Effects of Alcohol {#s1_2}
------------------------------------------------

At low doses, alcohol stimulates locomotor activity ([@B52]). This activation, which is thought to occur through the stimulation of the mesolimbic system, is hypothesized to be an index of its abuse liability ([@B49]).

The role of Sig-1R in alcohol-induced locomotion has been studied in mice. Although Sig-1R agonists and antagonists *per se* fail to influence locomotor activity, Maurice and colleagues demonstrated that Sig-1R blockade*via* the selective antagonist N-\[2-(3,4-dichlorophenyl)ethyl\]-N-methyl-2-(dimethylamino)ethylamine (BD-1047) inhibits the increase in locomotor activity induced by 1 g/kg of ethanol, in a dose-dependent manner ([@B39]). However, treatment with the Sig-1R selective agonist 2-(4-morpholine) ethyl 1-phenylcyclohexame-1-carboxylate (PRE-084) fails to influence alcohol-induced locomotion ([@B38]). This could be indicative of Sig-1R antagonists decreasing the response of the mesolimbic dopamine system. Interestingly, Sig-1R agonists have been shown to increase cocaine and methamphetamine-induced locomotor activity, while antagonists have been shown to decrease this response ([@B64]; [@B33]). The reason why Sig-1R agonists increase cocaine and methamphetamine-induced locomotor activity but fail to influence alcohol-induced locomotor activity is unclear, and it may be related to the specific mechanisms of action of psychostimulants.

Despite the fact that ethanol-induced locomotion stimulation is easily observed in Swiss mice, C57BL/6J mice are not as sensitive to the stimulatory effects of ethanol ([@B8]; [@B39]; [@B65]). To unmask the sedative effects of alcohol in C57BL/6J mice, ethanol is often co-administered with the benzodiazepine partial inverse agonist RO15-4513 ([@B8]). [@B65] employed this technique to examine the stimulatory effects in C57BL/6J lacking the *SIGMAR1* gene, which encodes the Sig-1R. Sig-1R KO mice were found to be less sensitive to the locomotor stimulating effects of 1.5 g/kg alcohol when compared to WT ([@B65]). As the stimulant effects of alcohol are thought to be related to its motivational and rewarding properties ([@B49]), the reduced sensitivity of Sig-1R KO mice to the stimulant effects of alcohol may reflect a reduced sensitivity to its motivational effects, which may, in turn, be responsible for their increased alcohol intake (i.e., higher amounts of alcohol required to feel euphoric effects) ([@B65]).

At high doses, alcohol acts as a central nervous system depressant. A single study investigated the effects of Sig-1R ligands on ethanol-induced sedation and found that Sig-1R KO do not differ from WT in either loss of righting reflex or sleep duration, suggesting that Sig-1R is not involved in the sedative effects of ethanol ([@B65]). These studies corroborate the notion that Sig-1Rs are involved in the stimulatory, but not the sedating, effects of ethanol.

Sigma Receptors and the Rewarding Properties of Alcohol {#s1_3}
-------------------------------------------------------

One of the most common tests to examine the rewarding properties of substances in animals is the place conditioning paradigm. The systemic administration of the selective Sig-1R agonist PRE-084 prior to ethanol enhances ethanol-induced CPP ([@B39]). Studies using intracerebroventricular administration of the same agonist also showed a facilitation of the acquisition of ethanol-induced CPP ([@B9]). Moreover, pretreatment with the Sig-1R antagonist BD-1047, administered during conditioning, blocks the acquisition of ethanol-induced CPP ([@B39]), while its intracerebroventricular administration has been shown to reduce both acquisition and expression ([@B9]). Lastly, neither Sig-1R agonists nor antagonists affect place preference when administered alone ([@B54]; [@B39]). Altogether, these studies show that Sig-Rs bidirectionally modulate the rewarding properties of alcohol.

Sigma Receptors and Alcohol Drinking {#s1_4}
------------------------------------

Evidence from both human and animal studies strongly implicates Sig-1Rs involvement in alcohol drinking. In relation to preclinical studies, these have all been performed in rodents and they can be divided into two types: passive home cage alcohol drinking studies and active operant alcohol self-administration studies.

### Home Cage Alcohol Drinking {#s1_4_1}

Many home cage drinking studies have been performed in The Scripps Research Institute (TSRI) Sardinian alcohol-preferring rats (Scr:sP), a line that descends directly from Sardinian alcohol preferring rats, which were selectively bred to drink high amounts of alcohol ([@B12]; [@B61]). Ethanol-naïve Scr:sP rats have elevated Sig-1R levels in the NAcc when compared to ethanol-naïve outbred Wistar rats ([@B10]). After 4 weeks of voluntary ethanol consumption, Sig-1R levels in the NAcc of Scr:sP rats returned back to baseline, suggesting that this could be a mechanism for the reduced motivation to drink after chronic drinking ([@B10]). Interestingly, the changes in protein level only occurred in the NAcc and not in the central nucleus of the amygdala, perhaps implicating the mesolimbic dopaminergic system ([@B10]). This is consistent with previous studies demonstrating the modulation of dopaminergic neurotransmission by Sig-1Rs ([@B5]; [@B44]; [@B45]). In line with these findings, the selective Sig-1R antagonists NE-100 and BD-1063 both reduce ethanol home cage drinking in Scr:sP rats, without affecting total fluid intake or food intake ([@B60]; [@B10]). NE-100 also fails to affect food intake or sucrose preference, suggesting that the effects of the drug are selective for alcohol ([@B60]). However, in that study, rats developed tolerance to NE-100 treatment within 1 week, similar to opioid receptor antagonist treatments ([@B47]; [@B60]).

Sig-1R KO mice exhibit increased alcohol preference and drink more alcohol compared to WT mice ([@B60]; [@B65]). The effect observed is specific for alcohol, as genotypes did not differ in their intake or preference for either the bitter tasting quinine or the sweet tasting saccharin, ruling out altered taste perception ([@B65]). The data obtained in Sig-1R KO may appear counterintuitive and in contrast with the general hypothesis that Sig-1R hyperactivity contributes to excessive ethanol intake. However, it is possible that developmental compensatory changes in expression of other genes may occur in Sig-1R KO mice, e.g., an up-regulation of Sig-2Rs, which may explain some of the observed effects.

### Operant Alcohol Self-Administration {#s1_4_2}

A method used to assess the reinforcing properties of alcohol is the use of operant conditioning, where rodents must lever press in order to obtain alcohol. Sig-R activation *via* daily systemic treatment of the Sig-1R/Sig-2R agonist 1,3-di-(2-tolyl)guanidine (DTG) is able to induce binge-like drinking (defined as blood alcohol concentration \>80 mg/dl) in Scr:sP rats under a fixed ratio 1 ratio of reinforcement, effect blocked by the selective Sig-1R antagonist BD-1063 ([@B58]). Consistent with a bidirectional modulation of alcohol self-administration, treatment with the selective Sig-1R antagonist BD-1063 decreases ethanol responding in Scr:sP rats in a dose-dependent manner ([@B59]).

Another schedule of reinforcement widely used in psychopharmacological research on alcohol is the progressive ratio schedule of reinforcement, which allows studying subjects' motivation to obtain the reinforcer ([@B24]). Daily systemic treatment of DTG increases, whereas acute BD-1063 administration decreases, the breakpoint for alcohol in Scr:sP rats, thus demonstrating the bi-directional role of Sig-1R also in modulating the motivational properties of ethanol ([@B59]; [@B58]).

Additional studies examined the role of Sig-1R in alcohol dependence in Wistar rats. Dependence was induced *via* chronic intermittent ethanol (CIE) vapor exposure, and this method has been shown to result in high blood alcohol levels (150--200 mg%), compulsive drinking, elevated anxiety, and increased ethanol intake during withdrawal (for review, see [@B66]). Pretreatment with the selective Sig-1R antagonist BD-1063 reduces ethanol self-administration in dependent, but not in non-dependent, outbred Wistar rats, without affecting water or saccharin intake, suggesting that Sig-1Rs modulate both genetic and environmental excessive drinking ([@B59]). In addition, compared to ethanol naïve Wistar rats, ethanol-dependent Wistar rats during acute withdrawal and ethanol naïve Scr:sP rats had significantly less Sig-1R mRNA in the NAcc, indicating that repeated cycles of intoxication followed by withdrawal mirror the phenotype observed in Scr:sP rats ([@B59]).

Lastly, repeated DTG administration in Scr:sP rats results in an increase in μ- and δ-opioid receptor gene expression in the ventral tegmental area (VTA) ([@B58]), indicating that Sig-R activation may lead to disinhibition of the mesolimbic dopaminergic VTA-NAcc pathway, resulting in increased dopamine release and increased reward sensitivity.

Sigma Receptors and Relapse-Like Behaviors {#s1_5}
------------------------------------------

Relapse after abstinence remains one of the most problematic barriers to treating AUDs. Cravings, or tenacious urges, to drink alcohol or engage in alcohol-seeking behaviors often occur during periods of abstinence and result in relapse ([@B35]). In rodents, this may be modeled by exposing animals to alcohol, then forcing them to abstain for a period of time, and lastly presenting alcohol again. Under these conditions, vehicle-treated abstinent Scr:sP rats dramatically increase their ethanol intake upon renewed presentation of alcohol, and blocking Sig-1R with the selective Sig-1R antagonist NE-100 blocks this ethanol deprivation effect ([@B60]). This study thus paves the way for more research into the role of Sig-1R in behaviors related to alcohol-seeking and relapse.

Another procedure is the priming-induced alcohol-seeking method, which mimics the human condition known as "one drink, one drunk," initially described by Jellinek and later validated by Hodgson and colleagues ([@B26]; [@B23]). In the context of reinstatement of ethanol-induced CPP, the administration of the selective Sig-1R agonist PRE-084 intracerebroventricularly was shown to be sufficient to induce reinstatement ([@B9]). Furthermore, pretreatment with the Sig-1R antagonist BD-1047 dose-dependently blocks both ethanol-induced and PRE-084-induced reinstatement, thus confirming that Sig-1R activation is required for priming-induced reinstatement ([@B9]).

Another important factor for relapse is the powerful effect that drug-paired cues exert on behavior. Selectively antagonizing Sig-1R with BD-1047 blocks reinstatement induced by ethanol- or palatable food-associated cues ([@B34]), thus indicating that this modulation is not specific to drug reward as it also applies to seeking behavior for highly palatable food. In a seeking-taking chained second-order schedule of reinforcement, in which an alcohol-associated incentive stimulus maintains alcohol-seeking behavior ([@B15]), the Sig-1R selective antagonist BD-1063 dose-dependently reduces alcohol-seeking behavior ([@B10]), suggesting a role for Sig-1R in incentive motivational mechanisms controlling ethanol-seeking and intake. Together, these studies provide insight into the critical role of the Sig-1R system in relapse-related behaviors.

Sigma Receptors and Cognitive Impairment During Alcohol Withdrawal {#s1_6}
------------------------------------------------------------------

Withdrawal after chronic alcohol consumption has been linked to deficits in cognitive function in human subjects ([@B58]). While the Sig-R system has been highly implicated in cognitive function ([@B37]), only few studies have examined the putative role of Sig-R system in chronic alcohol-induced cognitive impairment.

Using the novel object recognition task, [@B40] assessed cognitive function during protracted withdrawal in mice that had undergone chronic alcohol consumption (4 months). Alcohol withdrawn mice showed increased anxiety-like behaviors, elevated locomotion, and impaired object recognition; systemic administration of either the Sig-1R selective antagonist BD-1047 or the selective agonist igmesine is able to restore the habituation response (defined as decreased interactions with previously presented objects), but only the latter corrected reactions to spatial change and novelty ([@B40]). These mice also show upregulated hippocampal Sig-1R expression, which normalized after repeated administration of either Sig-1R ligand ([@B40]), indicating that Sig-1R levels may be responsible for the cognitive deficits seen in alcohol withdrawal.

Although the object recognition task provides direct evidence for the role of Sig-1R in cognition, other studies have used slice electrophysiology to examine the role of Sig-1Rs in hippocampal long-term potentiation (LTP). Initial studies that investigated the effect of CIE *via* vapor on LTP development in stimulatory CA1 synapses found juvenile rats in withdrawal from CIE vapors and increased NMDAR independence compared to their non-CIE vapor-treated counterparts ([@B56]). Furthermore, this increase in NMDAR independence in LTP is blocked by administration of the Sig-1R antagonist BD-1047, thus providing evidence for the role of the Sig-1R.

Subsequent studies found that early adolescent CIE vapor rats in withdrawal show depressed LTP excitability after high amplitude stimulus compared to controls ([@B55]). The decreases in action potential spike amplitude and excitatory postsynaptic potentiation in these subjects are reverted back to normal values by the Sig-1R antagonist BD-1047, suggesting that alcohol withdrawal may activate Sig-1Rs and therefore dampen the excitatory inputs during LTP ([@B55]). A recent study found that the decreased levels of neuron-specific nuclear protein/Fox-03 caused by CIE application to hippocampal explants can be reversed by treatment with the Sig-1R antagonist BD-1047 ([@B51]).

Together, these results indicate a strong role for Sig-1Rs in alcohol withdrawal-related neuroadaptations and symptomatology.

Limitations {#s1_7}
-----------

The studies reviewed in this manuscript have all focused on preclinical work performed in rodents. However, it is important to note that many of the studies involve animals consuming high amounts of alcohol and, therefore, caution should be exerted before extrapolating the results to humans. A single human study has so far shown a possible role for Sig-1R in AUD, specifically that a Japanese population of alcoholic subjects display three polymorphisms in the 5' untranslated region of the gene coding Sig-1Rs (*SIGMAR1*) that are highly associated with alcoholism ([@B41]). Additional human studies are indeed warranted to confirm that the rodent studies mentioned in this review have a translational value.

It is also important to note that all of the studies described in this review were performed in male animals. Since some neurobiological mechanisms of AUD are sexually dimorphic and alcohol use does differ between men and women ([@B14]), further studies hold potential for providing essential information regarding this gap.

Concluding Remarks {#s1_8}
------------------

The Sig-R system is proving to be a promising pharmacological target for AUD treatment. In various animal models, Sig-1R antagonists reduce alcohol consumption, motivation to drink, and alcohol-seeking behavior, demonstrating a critical role for Sig-1Rs in these behaviors (see [**Table 2**](#T2){ref-type="table"} **)**. Since current Food and Drug Administration (FDA)-approved medications for AUD, i.e., disulfiram, naltrexone, and acamprosate, have been shown to have limited efficacy, Sig-1R targeting drugs could represent a promising therapeutic option. Yet, the precise routes of action through which the Sig-1R system impacts alcohol's effects are unknown, and therefore, additional studies to unveil these mechanisms and the relationship between Sig-1R and alcohol will be vital to comprehending AUD from a neurobiological standpoint and developing novel and more efficacious pharmacological therapeutics.

###### 

Summary of the pharmacological findings included in this review.

  Behavior                                           Drug type                                                                                             Results                                                                      Citation
  -------------------------------------------------- ----------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------- -----------------
  Locomotor                                          Antagonist (BD-1047)                                                                                  Inhibited ethanol-induced (1 g/kg) locomotor activity                        ([@B39])
  Agonist (PRE-084)                                  No effect on ethanol-induced (0.5 g/kg) locomotor activity                                            ([@B39])                                                                     
  Genetic KO                                         Inhibited ethanol-induced (1.5 g/kg) locomotor activity                                               ([@B65])                                                                     
  Genetic KO                                         No differences in sedative effects of alcohol                                                         ([@B65])                                                                     
  Rewarding properties                               Agonist (PRE-084)                                                                                     Enhanced CPP                                                                 ([@B9]; [@B39])
  Antagonist (BD-1047)                               Diminished CPP                                                                                        ([@B9])                                                                      
  Home cage drinking                                 Antagonist (NE-100)                                                                                   Reduced ethanol intake                                                       ([@B60])
  Antagonist (BD-1063)                               Reduced ethanol intake                                                                                ([@B10])                                                                     
  Genetic KO                                         Increased ethanol intake and preference                                                               ([@B65])                                                                     
  Operant self-administration                        Agonist (DTG)                                                                                         Induce binge-like drinking                                                   ([@B58])
  Antagonist (BD-1063)                               Reduced ethanol intake                                                                                ([@B59])                                                                     
  Motivation to drink                                Agonist (DTG)                                                                                         Increased breakpoint                                                         ([@B57])
  Antagonist (BD-1063)                               Decreased breakpoint                                                                                  ([@B59])                                                                     
  Alcohol deprivation effect                         Antagonist (NE-100)                                                                                   Inhibited alcohol deprivation effect                                         ([@B60])
  Reinstatement of CPP                               Agonist (PRE-084)                                                                                     Induced CPP                                                                  ([@B9])
  Antagonist (BD-1047)                               Inhibited ethanol and PRE-084-induced reinstatement                                                   ([@B9])                                                                      
  Reinstatement of operant behavior                  Antagonist (BD-1047)                                                                                  Inhibited reinstatement of both food and alcohol cue-induced reinstatement   ([@B34])
  Seeking-taking chained schedule of reinforcement   Antagonist (BD-1063)                                                                                  Reduced alcohol-seeking                                                      ([@B10])
  Cognitive impairment during alcohol withdrawal     Agonist (igmesine)                                                                                    Restored cognitive responses in withdrawn mice                               ([@B40])
  Antagonist (BD-1047)                               Restored cognitive responses in withdrawn mice                                                        ([@B40])                                                                     
  LTP                                                Antagonist (BD-1047)                                                                                  Blocks increase in NMDAR-independent LTP seen in withdrawn rats              ([@B56])
  Antagonist (BD-1047)                               Blocks action potential spike amplitude and excitatory post-synaptic potentiation in withdrawn rats   ([@B55])                                                                     

This table summarizes the major findings presented.

BD-1047, N-\[2-(3,4-dichlorophenyl)ethyl\]-N-methyl-2-(dimethylamino)ethylamine; PRE-084, 2-(4-morpholine) ethyl 1-phenylcyclohexame-1-carboxylate; KO, sigma-1 knockout; NMDAR, N-methyl-D-aspartate receptor; LTP, long-term potentiation; BD-1063, 1-\[2-(3,4-dichlorophenyl)ethyl\]-4-methylpiperazine; NE-100, 4-methoxy-3-(2-phenylethoxy)-N,N-dipropylbenzeneethanamine; CPP, conditioned place preference; DTG, 1,3-Di-o-tolylguanidine.
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